Therapy Areas: Diabetes
Reata Pharmaceuticals receives USD30m milestone payment from Japanese licensee
31 August 2018 -

Reata Pharmaceuticals Inc (Nasdaq: RETA) has received a USD30m milestone payment from its licensee, Kyowa Hakko Kirin Co Ltd, following the start of a clinical trial in Japan, the biopharmaceutical company revealed on Thursday.

The Phase 3 AYAME trial will assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease.

Reata granted Kyowa Hakko Kirin an exclusive licence in December 2009 to develop and commercialise bardoxolone in renal disease and certain other indications in Japan, China, Taiwan, South Korea and Southeast Asia. Last year, the Japanese company reported positive results from the Phase 2 TSUBAKI trial of bardoxolone in patients with type 2 diabetes and chronic kidney disease.

Around 700 diabetic kidney disease patients will take part in the Phase 3 trial, which is expected to be completed in March 2022.

Kyowa Hakko Kirin is also collaborating with Reata in Japan on the ongoing Phase 3 CARDINAL trial of bardoxolone for the treatment of Alport syndrome, a severe, hereditary form of chronic kidney disease.

Login
Username:

Password: